No summary available.

Coloplast (OTCMKTS: CLPBY ) just reported results for the third quarter of 2024. Coloplast reported earnings per share of 8 cents. The company reported revenue of $993.51 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post CLPBY Stock Earnings: Coloplast Reported Results for Q3 2024 appeared first on InvestorPlace .

No summary available.

9M 2023/24 Interim financial results, 9M 2023/24 1 October 2023 - 30 June 2024 Coloplast delivered 8% organic growth and an EBIT margin1) of 27% in Q3, with 11% growth in absolute EBIT1). Reported revenue in DKK grew 13% which includes 4%-points contribution from Kerecis (underlying growth of around 35%). Organic growth rates by business area: Ostomy Care 8%, Continence Care 8%, Voice Jetzt den vollständigen Artikel lesen

https://www.investing.com/news/company-news/coloplast-stock-upgraded-by-barclays-cites-growth-prospects-93CH-3528209

Coloplast shows strong growth potential through innovative products, solid management, and focus on market expansion. See why CLPBF stock is hold rated.